Prexasertib - Cancer Science

What is Prexasertib?

Prexasertib is an investigational drug being studied for its potential to treat various forms of cancer. It is a small-molecule inhibitor that specifically targets checkpoint kinase 1 (CHK1), an enzyme that plays a crucial role in the cell cycle and DNA damage response.

How Does Prexasertib Work?

Prexasertib works by inhibiting CHK1, thereby preventing the repair of damaged DNA in cancer cells. This leads to an accumulation of DNA damage and ultimately induces cell death in cancer cells. The drug is particularly effective in cells with defective DNA repair mechanisms, such as those with mutations in BRCA1 or BRCA2.

What Types of Cancer is Prexasertib Being Studied For?

Prexasertib has shown promise in preclinical studies and early clinical trials for a variety of cancers, including ovarian cancer, breast cancer, lung cancer, and colorectal cancer. It is also being explored in combination with other therapies to enhance its efficacy.

What Are the Results of Clinical Trials?

Early-phase clinical trials have demonstrated that prexasertib is effective in reducing tumor size and improving patient outcomes in certain types of cancer. However, more extensive Phase III trials are needed to confirm these findings and establish the drug's safety and efficacy profile.

What Are the Side Effects of Prexasertib?

Like many cancer therapies, prexasertib can cause a range of side effects. Common side effects include fatigue, nausea, vomiting, and low blood cell counts. It's important for patients to be monitored closely during treatment to manage these side effects effectively.

What is the Future of Prexasertib in Cancer Treatment?

The future of prexasertib looks promising, especially as researchers continue to explore its use in combination with other treatments, such as immunotherapy and chemotherapy. Ongoing and future clinical trials will provide more insights into its potential to become a standard part of cancer treatment regimens.

Conclusion

Prexasertib represents an exciting advancement in the field of cancer treatment. By targeting CHK1 and disrupting the DNA damage response in cancer cells, it offers a novel approach to combating various types of cancer. Ongoing research and clinical trials will be crucial in determining its ultimate role in oncology.

Relevant Publications

CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer.

Issue Release: 2024

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.

Issue Release: 2024

Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells.

Issue Release: 2024

Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells.

Issue Release: 2024

Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition.

Issue Release: 2024

Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer.

Issue Release: 2024

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing.

Issue Release: 2023

Using the LeiCNS-PK3.0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in Mice.

Issue Release: 2023

Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells.

Issue Release: 2022

Inhibition of Chk2 promotes neuroprotection, axon regeneration, and functional recovery after CNS injury.

Issue Release: 2022

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.

Issue Release: 2022

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy.

Issue Release: 2022

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.

Issue Release: 2022

Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor.

Issue Release: 2022

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

Issue Release: 2022

Aberrant Activation of Cell-Cycle-Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma.

Issue Release: 2022

Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis and represses tumour growth in an xenograft model.

Issue Release: 2022

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention.

Issue Release: 2022

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.

Issue Release: 2021

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.

Issue Release: 2021

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics